GlassScriptPhysician profile
Beth Lynn Stefanchik
NPI 1992942551
$3,912.43
in general payments reported to CMS, 2019-2025
28 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $205 · 2021: $606 · 2022: $543 · 2023: $353 · 2024: $563 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $35.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.07 |
| Education | $35.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.57 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $283.28 | 2019-2024 | Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $274.47 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $267.32 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $235.82 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $229.81 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $226.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $223.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $210.04 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $208.39 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $151.42 | 2019-2025 | Rayaldee |
| Alnylam Pharmaceuticals INC. | $139.55 | 2023-2025 | Givlaari |
| Travere Therapeutics, INC. | $131.06 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $119.06 | 2021-2024 | Lupkynis |
| Amgen INC. | $94.48 | 2019-2025 | Tavneos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.78 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $81.81 | 2023-2025 | Tarpeyo |
| Lilly USA, LLC | $73.70 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $56.23 | 2019-2024 | Ultomiris |
| Ardelyx, INC. | $54.54 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $49.11 | 2021-2024 | Jesduvroq |
| Nxstage Medical, INC. | $41.49 | 2022-2023 | Nxstage System One |
| Takeda Pharmaceuticals U.S.A., INC. | $36.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.30 | 2022-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $29.68 | 2022-2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $23.17 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.05 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Stefanchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.